DrugPatentWatch Database Preview
Patent: 10,261,087
» See Plans and Pricing
Summary for Patent: 10,261,087
| Title: | Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (VEGF) |
| Abstract: | The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor. |
| Inventor(s): | Heidecke; Harald (Berlin, DE), Schulze-Forster; Kai (Berlin, DE) |
| Assignee: | CELLTREND GMBH (Luckenwal, DE) |
| Application Number: | 15/115,902 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,261,087
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | EYLEA | aflibercept | INJECTABLE; INJECTION | 125387 | 001 | 2011-11-18 | Start Trial | CELLTREND GMBH (Luckenwal, DE) | 2034-02-04 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | CELLTREND GMBH (Luckenwal, DE) | 2034-02-04 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | CELLTREND GMBH (Luckenwal, DE) | 2034-02-04 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
